GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Price-to-Owner-Earnings

Cantargia AB (FRA:7V3) Price-to-Owner-Earnings : (As of May. 23, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Price-to-Owner-Earnings?

As of today (2025-05-23), Cantargia AB's share price is €0.1192. Cantargia AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Cantargia AB's Price-to-Owner-Earnings or its related term are showing as below:


FRA:7V3's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.53
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-23), Cantargia AB's share price is €0.1192. Cantargia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.08. Therefore, Cantargia AB's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-23), Cantargia AB's share price is €0.1192. Cantargia AB's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.08. Therefore, Cantargia AB's PE Ratio without NRI for today is At Loss.


Cantargia AB Price-to-Owner-Earnings Historical Data

The historical data trend for Cantargia AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Price-to-Owner-Earnings Chart

Cantargia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cantargia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cantargia AB's Price-to-Owner-Earnings

For the Biotechnology subindustry, Cantargia AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Price-to-Owner-Earnings falls into.


;
;

Cantargia AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cantargia AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1192/-0.05
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantargia AB  (FRA:7V3) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Cantargia AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantargia AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines